BEGIN:VCALENDAR VERSION:2.0 PRODID:VideoCast CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT SUMMARY:COVID-19: Developing a Vaccine During a Pandemic DTSTART:20210204T170000Z DTEND:20210204T180000Z DTSTAMP:20210208T150300Z UID:Videocast--41236 LOCATION:https://videocast.nih.gov/watch=41236 DESCRIPTION:Dan Barouch\, M.D.\, Ph.D.\, William Bosworth Castle Professor of Medicine and Professor of Immunology\, Harvard Medical School\, Director\, Center for Virology and Vaccine Research\, Beth Israel Deaconess Medical Center\nCOVID-19 Scientific Interest Group\n\nDr. Barouch is the William Bosworth Castle Professor of Medicine and Professor of Immunology at Harvard Medical School and director of the Center for Virology and Vaccine Research at the Beth Israel Deaconess Medical Center. His talk will outline the current state of the COVID-19 vaccine field and will describe the development of the Ad26.COV2.S vaccine — a recombinant\, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.\n\nMy laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. I have also recently demonstrated the therapeutic efficacy of potent monoclonal antibodies and the early seeding of the viral reservoir. My laboratory received three NIH U19 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program grants in 2005\, 2008\, and 2012 to construct alternative serotype adenovirus vaccine vectors\, to explore their immunogenicity and protective efficacy in rhesus monkeys\, and to advance optimal vaccine candidates into clinical trials. Four phase 1 clinical trials with these vectors have been completed in the United States and sub-Saharan Africa. My laboratory also received an NIH U19 grant in 2011 to establish a consortium for AIDS vaccine research in nonhuman primates and four Gates Foundation consortium grants in 2011\, 2012\, 2013\, and 2014 to develop replicating adenovirus vectors\, nonhuman primate adenovirus vectors\, novel Env protein immunogens\, and therapeutic broadly neutralizing monoclonal antibodies in both preclinical studies and clinical trials.\n\nFor more information go to https://oir.nih.gov/sigs/covid-19-scientific-interest-group https://oir.nih.gov/sigs/covid-19-scientific-interest-group X-ALT-DESC;FMTTYPE=text/html:\n\n
\n